Figure 2 shows that during treatment Subject
2's daily intake of caffeine decreased from his
baseline mean of 1147 mg to a mean of 357
mg (a decrease of 790 mg or over six cups of
brewed coffee) and that he never exceeded criterion.
His mean daily intake of caffeine during
the 10-month follow-up was 250 mg. Subject 2
reported that his low, stable posttreatment consumption
of caffeine through the 3-month
follow-up was because he had stopped brewing
coffee at work which prior to treatment had
been his major source of caffeine. Between the
3- and 10-month follow-up, Subject 2 reported